journal article·2022-03-11Open access

A Brief Review of Machine Learning-Based Bioactive Compound Research

Jihye Park, Bo Ram Beck, Hoo Hyun Kim, Sangbum Lee, Keunsoo Kang

Applied Sciences· Volume 12· Issue 6

Abstract

Bioactive compounds are often used as initial substances for many therapeutic agents. In recent years, both theoretical and practical innovations in hardware-assisted and fast-evolving machine learning (ML) have made it possible to identify desired bioactive compounds in chemical spaces, such as those in natural products (NPs). This review introduces how machine learning approaches can be used for the identification and evaluation of bioactive compounds. It also provides an overview of recent research trends in machine learning-based prediction and the evaluation of bioactive compounds by listing real-world examples along with various input data. In addition, several ML-based approaches to identify specific bioactive compounds for cardiovascular and metabolic diseases are described. Overall, these approaches are important for the discovery of novel bioactive compounds and provide new insights into the machine learning basis for various traditional applications of bioactive compound-related research.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Computational Drug Discovery Methods · Microbial Natural Products and Biosynthesis · Bioinformatics and Genomic Networks

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Microbiology, College of Science & Technology, Dankook University, Cheonan 31116, Korea

Deargen Inc., 193, Munji-ro, Yuseong-gu, Daejeon 34051, Korea

Department of Software, College of Software Convergence, Dankook University, Yongin 16890, Korea

Funding

Korea Food Research Institute · National Research Foundation of Korea (NRF) grants funded by the Korean government (MSIT) · National R&D Program for Cancer Control, Ministry of Health & Welfare, Republic of Korea · Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education · the Research-Focused Department Promotion Project as a part of the University Innovation Sup-port Program

References (94)

Show source-provided references
1. Natural products as sources of new drugs from 1981 to 201410.1021/acs.jnatprod.5b01055 ↗
2. Natural products as sources of new drugs over the 30 years from 1981 to 201010.1021/np200906s ↗
3. Thomford, N.E., Senthebane, D.A., Rowe, A., Munro, D., Seele, P., Maroyi, A., and Dzobo, K. (2018). Natural products for drug discovery in the 21st century: Innovations for novel drug discovery. Int. J. Mol. Sci., 19.10.3390/ijms19061578 ↗
4. Discovery and resupply of pharmacologically active plant-derived natural products: A review10.1016/j.biotechadv.2015.08.001 ↗
5. The re-emergence of natural products for drug discovery in the genomics era10.1038/nrd4510 ↗
6. Waltenberger, B., Mocan, A., Šmejkal, K., Heiss, E.H., and Atanasov, A.G. (2016). Natural products to counteract the epidemic of cardiovascular and metabolic disorders. Molecules, 21.10.3390/molecules21060807 ↗
7. The raison d’ĕtre of secondary plant substances; These odd chemicals arose as a means of protecting plants from insects and now guide insects to food10.1126/science.129.3361.1466 ↗
8. Many approved drugs have bioactive analogs with different target annotations10.1208/s12248-014-9621-8 ↗
9. From micrograms to grams: Scale-up synthesis of eribulin mesylate10.1039/c3np70051h ↗
10. The discovery of first-in-class drugs: Origins and evolution10.1038/nrd4336 ↗
11. Oral druggable space beyond the rule of 5: Insights from drugs and clinical candidates10.1016/j.chembiol.2014.08.013 ↗
12. Navigating chemical space for biology and medicine10.1038/nature03193 ↗
13. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings10.1016/S0169-409X(00)00129-0 ↗
14. The art and practice of structure-based drug design: A molecular modeling perspective10.1002/(SICI)1098-1128(199601)16:1<3::AID-MED1>3.0.CO;2-6 ↗
15. NP navigator: A new look at the natural product chemical space10.1002/minf.202100068 ↗
16. Natural product-informed exploration of chemical space to enable bioactive molecular discovery10.1039/D0MD00376J ↗
17. ChemGPS-NP: Tuned for navigation in biologically relevant chemical space10.1021/np070002y ↗
18. Grazina, L., Rodrigues, P.J., Igrejas, G., Nunes, M.A., Mafra, I., Arlorio, M., Oliveira, M.B.P.P., and Amaral, J.S. (2020). Machine learning approaches applied to GC-FID fatty acid profiles to discriminate wild from farmed salmon. Foods, 9.10.3390/foods9111622 ↗
19. Artificial intelligence in drug discovery and development10.1016/j.drudis.2020.10.010 ↗
20. Success stories of AI in drug discovery—Where do things stand?10.1080/17460441.2022.1985108 ↗
21. Artificial intelligence in drug discovery: Recent advances and future perspectives10.1080/17460441.2021.1909567 ↗
22. DeepDTA: Deep drug–target binding affinity prediction10.1093/bioinformatics/bty593 ↗
23. Moon, S., Zhung, W., Yang, S., Lim, J., and Kim, W.Y. (2022). PIGNet: A physics-informed deep learning model toward generalized drug-target interaction predictions. Chem. Sci., in press.10.1039/D1SC06946B ↗
24. Deep docking: A deep learning platform for augmentation of structure based drug discovery10.1021/acscentsci.0c00229 ↗
25. Three-dimensional convolutional neural networks and a cross-docked data set for structure-based drug design10.1021/acs.jcim.0c00411 ↗
26. FP-ADMET: A compendium of fingerprint-based ADMET prediction models10.1186/s13321-021-00557-5 ↗
27. ADMET modeling approaches in drug discovery10.1016/j.drudis.2019.03.015 ↗
28. Bayer’s in silico ADMET platform: A journey of machine learning over the past two decades10.1016/j.drudis.2020.07.001 ↗
29. SMILES, a chemical language and information system. 1. Introduction to methodology and encoding rules
30. PubChem in 2021: New data content and improved web interfaces10.1093/nar/gkaa971 ↗
31. The ChEMBL Database in 201710.1093/nar/gkw1074 ↗
32. ZINC 15-ligand discovery for everyone10.1021/acs.jcim.5b00559 ↗
33. 4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid is a highly effective inhibitor both of the sialidase (neuraminidase) and of growth of a wide range of influenza A and B viruses in vitro10.1128/AAC.37.7.1473 ↗
34. Announcing the worldwide protein data bank10.1038/nsb1203-980 ↗
35. Proteogenomics: Integrating next-generation sequencing and mass spectrometry to characterize human proteomic variation10.1146/annurev-anchem-071015-041722 ↗
36. NCBI (2018). Resource coordinators database resources of the national center for biotechnology information. Nucleic Acids Res., 46, D8–D13.
37. UniProt: The Universal Protein knowledgebase10.1093/nar/gky092 ↗
38. The protein data bank10.1093/nar/28.1.235 ↗
39. Review on natural products databases: Where to find data in 202010.1186/s13321-020-00424-9 ↗
40. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles10.1073/pnas.0506580102 ↗
41. Massive mining of publicly available RNA-seq data from human and mouse10.1038/s41467-018-03751-6 ↗
42. The mutational constraint spectrum quantified from variation in 141,456 humans10.1038/s41586-020-2308-7 ↗
43. Chemical space and biology10.1038/nature03192 ↗
44. Characterization of the chemical space of known and readily obtainable natural products10.1021/acs.jcim.8b00302 ↗
45. Quantifying the chemical beauty of drugs10.1038/nchem.1243 ↗
46. In silico ADME/tox profiling of natural products: A focus on BIOFACQUIM10.1021/acsomega.0c01581 ↗
47. ADMETlab: A platform for systematic ADMET evaluation based on a comprehensively collected ADMET database10.1186/s13321-018-0283-x ↗
48. ADME-space: A new tool for medicinal chemists to explore ADME properties10.1038/s41598-017-06692-0 ↗
49. ProTox-II: A webserver for the prediction of toxicity of chemicals10.1093/nar/gky318 ↗
50. ADMET in silico modelling: Towards prediction paradise?10.1038/nrd1032 ↗
51. Improvement in ADMET prediction with multitask deep featurization10.1021/acs.jmedchem.9b02187 ↗
52. SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules10.1038/srep42717 ↗
53. Deep learning approaches in predicting ADMET properties10.4155/fmc-2020-0259 ↗
54. A guide to machine learning for biologists10.1038/s41580-021-00407-0 ↗
55. Best practices in machine learning for chemistry10.1038/s41557-021-00716-z ↗
56. (2021). Moving towards reproducible machine learning. Nat. Comput. Sci., 1, 629–630.10.1038/s43588-021-00152-6 ↗
57. Patel, L., Shukla, T., Huang, X., Ussery, D.W., and Wang, S. (2020). Machine learning methods in drug discovery. Molecules, 25.10.3390/molecules25225277 ↗
58. Mirza, B., Wang, W., Wang, J., Choi, H., Chung, N.C., and Ping, P. (2019). Machine learning and integrative analysis of biomedical big data. Genes, 10.10.3390/genes10020087 ↗
59. Deep learning: New computational modelling techniques for genomics10.1038/s41576-019-0122-6 ↗
60. Shin, B., Park, S., Kang, K., and Ho, J.C. (2019). Self-attention based molecule representation for predicting drug-target interaction. arXiv.
61. Making sense of large-scale kinase inhibitor bioactivity data sets: A comparative and integrative analysis10.1021/ci400709d ↗
62. Comprehensive analysis of kinase inhibitor selectivity10.1038/nbt.1990 ↗
63. Prediction of natural product classes using machine learning and 13C NMR spectroscopic data10.1021/acs.jcim.0c00293 ↗
64. NAPROC-13: A database for the dereplication of natural product mixtures in bioassay-guided protocols10.1093/bioinformatics/btm516 ↗
65. A machine learning bioinformatics method to predict biological activity from biosynthetic gene clusters10.1021/acs.jcim.0c01304 ↗
66. A deep learning genome-mining strategy for biosynthetic gene cluster prediction10.1093/nar/gkz654 ↗
67. Long short-term memory10.1162/neco.1997.9.8.1735 ↗
68. Distributed representations of words and phrases and their compositionality
69. The pfam protein families database: Towards a more sustainable future10.1093/nar/gkv1344 ↗
70. Design of natural-product-inspired multitarget ligands by machine learning10.1002/cmdc.201900097 ↗
71. Cholinesterase inhibitors as Alzheimer’s therapeutics (review)
72. Scaffold hopping from natural products to synthetic mimetics by holistic molecular similarity10.1038/s42004-018-0043-x ↗
73. Identifying the macromolecular targets of de novo-designed chemical entities through self-organizing map consensus10.1073/pnas.1320001111 ↗
74. A computational method for unveiling the target promiscuity of pharmacologically active compounds10.1002/anie.201706376 ↗
75. Machine learning methods to predict the terrestrial and marine origin of natural products10.1002/minf.202060034 ↗
76. PPARγ signaling and metabolism: The good, the bad and the future10.1038/nm.3159 ↗
77. The many faces of PPARγ10.1016/j.cell.2005.11.026 ↗
78. From machine learning to natural product derivatives that selectively activate transcription factor PPARγ10.1002/cmdc.200900469 ↗
79. Zeidan, M., Rayan, M., Zeidan, N., Falah, M., and Rayan, A. (2017). Indexing natural products for their potential anti-diabetic activity: Filtering and mapping discriminative physicochemical properties. Molecules, 22.10.3390/molecules22091563 ↗
80. A deep learning-based approach for identifying the medicinal uses of plant-derived natural compounds10.3389/fphar.2020.584875 ↗
81. Immune cells in adipose tissue: Key players in metabolic disorders10.1016/j.diabet.2011.03.002 ↗
82. Inflammation and metabolic disorders10.1038/nature05485 ↗
83. Nature is the best source of anti-inflammatory drugs: Indexing natural products for their anti-inflammatory bioactivity10.1007/s00011-017-1096-5 ↗
84. Novel potential agents for ulcerative colitis by molecular topology: Suppression of IL-6 production in Caco-2 and RAW 264.7 cell lines10.1007/s11030-013-9458-6 ↗
85. Prediction of anti-inflammatory plants and discovery of their biomarkers by machine learning algorithms and metabolomic studies10.1055/s-0034-1396206 ↗
86. Linardatos, P., Papastefanopoulos, V., and Kotsiantis, S. (2020). Explainable AI: A review of machine learning interpretability methods. Entropy, 23.10.3390/e23010018 ↗
87. AutoML: A survey of the state-of-the-art10.1016/j.knosys.2020.106622 ↗
88. Coumarin derivatives: An updated patent review (2015–2016)10.1080/13543776.2017.1360284 ↗
89. Synthesis and biological evaluation of coumarin derivatives containing imidazole skeleton as potential antibacterial agents10.1016/j.ejmech.2017.11.100 ↗
90. Park, S., Ko, Y.H., Lee, B., Shin, B., and Beck, B.R. (2020, January 15). Abstract 35: Molecular optimization of phase III trial failed anticancer drugs using target affinity and toxicity-centered multiple properties reinforcement learning. Proceedings of the Poster Presentations—Proffered Abstracts, Ljubljana, Slovenia.10.1158/1557-3265.ADVPRECMED20-35 ↗
91. Optimization of molecules via deep reinforcement learning10.1038/s41598-019-47148-x ↗
92. Deep learning enables rapid identification of potent DDR1 kinase inhibitors10.1038/s41587-019-0224-x ↗
93. Shin, B., Park, S., Bak, J., and Ho, J.C. (2021, January 8). Controlled molecule generator for optimizing multiple chemical properties. Proceedings of the Conference on Health, Inference, and Learning, Virtual Event.10.1145/3450439.3451879 ↗
94. Structure-based de novo drug design using 3D deep generative models10.1039/D1SC04444C ↗